secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-08-03T20:15:24+00:00
Accession:  0001193125-26-330599
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline
--------------------------------------------------------------------------------

- Updated presentation includes ASCO 2026 data for VMT-α-NET in neuroendocrine tumors with 68 patients treated.
- VMT01 for melanoma shows preliminary anti-tumor activity at 3.0 mCi dose in ongoing Phase 1/2a.
- PSV359 targeting FAP-α for solid tumors is in Phase 1/2a with improved tumor retention.
- Company emphasizes 212Pb-based theranostic approach and direct-to-hospital delivery model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/0001193125-26-330599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526330599/catx-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer